Previous studies have demonstrated the effect of ruxolitinib in other hematological malignancies, showing inhibition of VEGF, HIF-1α expression, and angiogenesis of HEL leukemia cells [13], and a dose-dependent inhibition of cell proliferation with concurrent activation of apoptosis, a marked and rapid inhibition of STAT activation, and inhibition in DNA synthesis in CTCL cells [14]. This evidence concerns the gene HIF1A and leukemia.